Medicare Add-On Payments For New Dialysis Drugs Limited To ‘Innovative’ Products
Centers for Medicare and Medicaid Services narrows the types of drugs eligible for add-on payments in the Medicare end-stage renal program as it tries to balance efforts to promote innovation with controlling costs.
You may also be interested in...
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.
Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.